Opthea Limited (OPT) Announces Proposed $160M ADS IPO
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Opthea Announces Launch of Proposed Initial Public Offering in the United States
October 11, 2020 8:00 PM EDTMELBOURNE, Australia, Oct. 11, 2020 (GLOBE NEWSWIRE) -- Opthea Limited (ASX: OPT), a clinical stage biopharmaceutical company developing a novel therapy to treat highly prevalent and progressive retinal diseases, today announces the launch of its initial public offering (the Offering) of American Depositary Shares (ADS), each of which will represent eight of the Companys ordinary shares, in the United States. The target size of the Offering is US$160 million in gross proceeds. The Company also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of... More
